| Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells K Yacqub‐Usman, MR Pickard, GT Williams The prostate 75 (7), 693-705, 2015 | 118 | 2015 |
| Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas CV Duong, RD Emes, F Wessely, K Yacqub-Usman, RN Clayton, ... Endocrine-related cancer 19 (6), 805-816, 2012 | 71 | 2012 |
| Simultaneous SAXS and SANS analysis for the detection of toroidal supramolecular polymers composed of noncovalent supermacrocycles in solution MJ Hollamby, K Aratsu, BR Pauw, SE Rogers, AJ Smith, M Yamauchi, ... Angewandte Chemie 128 (34), 10044-10047, 2016 | 61 | 2016 |
| The pituitary tumour epigenome: aberrations and prospects for targeted therapy K Yacqub-Usman, A Richardson, CV Duong, RN Clayton, WE Farrell Nature Reviews Endocrinology 8 (8), 486-494, 2012 | 50 | 2012 |
| Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis H Al-Azzawi, K Yacqub-Usman, A Richardson, LJ Hofland, RN Clayton, ... Endocrinology 152 (2), 364-373, 2011 | 33 | 2011 |
| Epigenomic Silencing of the BMP-4 Gene in Pituitary Adenomas: A Potential Target for Epidrug-Induced Re-expression K Yacqub-Usman, CV Duong, RN Clayton, WE Farrell Endocrinology 153 (8), 3603-3612, 2012 | 32 | 2012 |
| Apoptosis in cancer cells is induced by alternative splicing of hnRNPA2/B1 through splicing of Bcl-x, a mechanism that can be stimulated by an extract of the South African … TJ Makhafola, M Mbele, K Yacqub-Usman, A Hendren, DB Haigh, ... Frontiers in Oncology 10, 547392, 2020 | 22 | 2020 |
| Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells MO Kitchen, K Yacqub-Usman, RD Emes, A Richardson, RN Clayton, ... Pituitary 18, 674-684, 2015 | 18 | 2015 |
| Preincubation of pituitary tumor cells with the epidrugs zebularine and trichostatin A are permissive for retinoic acid-augmented expression of the BMP-4 and D2R genes K Yacqub-Usman, CV Duong, RN Clayton, WE Farrell Endocrinology 154 (5), 1711-1721, 2013 | 17 | 2013 |
| The EFEMP1 gene: a frequent target for epigenetic silencing in multiple human pituitary adenoma subtypes CV Duong, K Yacqub-Usman, RD Emes, RN Clayton, WE Farrell Neuroendocrinology 98 (3), 200-211, 2013 | 14 | 2013 |
| Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts BP Sharpe, A Hayden, A Manousopoulou, A Cowie, RC Walker, ... Cell Reports Medicine 3 (6), 2022 | 13 | 2022 |
| Effect of combining EGFR tyrosine kinase inhibitors and cytotoxic agents on cholangiocarcinoma cells B Boonsri, K Yacqub-Usman, P Thintharua, KZ Myint, T Sae-Lao, P Collier, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2021 | 10 | 2021 |
| Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis K Supradit, B Boonsri, J Duangdara, T Thitiphatphuvanon, ... Toxicology in Vitro 82, 105385, 2022 | 7 | 2022 |
| Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates … M Wahid, B Pratoomthai, IU Egbuniwe, HR Evans, R Babaei-Jadidi, ... Cancer Immunology, Immunotherapy 72 (12), 4001-4014, 2023 | 5 | 2023 |
| Retroviral insertional mutagenesis implicates E3 ubiquitin ligase RNF168 in the control of cell proliferation and survival A Kizilors, MR Pickard, CE Schulte, K Yacqub-Usman, NJ McCarthy, ... Bioscience Reports 37 (4), BSR20170843, 2017 | 4 | 2017 |
| Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma KZ Myint, M Sueca-Comes, P Collier, B Balasubramanian, ... Frontiers in Oncology 13, 1184900, 2023 | 1 | 2023 |
| Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma B Balasubramanian, K Yacqub-Usman, S Venkatraman, KZ Myint, ... Cancers 15 (9), 2528, 2023 | 1 | 2023 |
| FGF signalling as a therapeutic target in Cholangiocarcinoma B Balasubramanian, KZ Myint, K Yacqub-Usman, S Venkatraman, ... Cancer Science 112, 419-419, 2021 | 1 | 2021 |
| Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation KZ Myint, B Balasubramanian, S Venkatraman, S Phimsen, S Sripramote, ... Pharmaceuticals 17 (2), 197, 2024 | | 2024 |
| ALK-independent Therapeutic Potential of Ceritinib in Cholangiocarcinoma KZ Myint, B Balasubramanian, S Venkatraman, J Jantra, K Chueajedton, ... CANCER SCIENCE 112, 536-536, 2021 | | 2021 |
